Copyright Reports & Markets. All rights reserved.

Global CAR T-Cell Therapy Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global CAR T-Cell Therapy Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Allogeneic
      • 1.4.3 Autologous
    • 1.5 Market by Application
      • 1.5.1 Global CAR T-Cell Therapy Market Share by Application (2014-2025)
      • 1.5.2 Hospitals
      • 1.5.3 Cancer Research Centers
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 CAR T-Cell Therapy Market Size
    • 2.2 CAR T-Cell Therapy Growth Trends by Regions
      • 2.2.1 CAR T-Cell Therapy Market Size by Regions (2014-2025)
      • 2.2.2 CAR T-Cell Therapy Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 CAR T-Cell Therapy Market Size by Manufacturers
      • 3.1.1 Global CAR T-Cell Therapy Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global CAR T-Cell Therapy Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global CAR T-Cell Therapy Market Concentration Ratio (CR5 and HHI)
    • 3.2 CAR T-Cell Therapy Key Players Head office and Area Served
    • 3.3 Key Players CAR T-Cell Therapy Product/Solution/Service
    • 3.4 Date of Enter into CAR T-Cell Therapy Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global CAR T-Cell Therapy Market Size by Type (2014-2019)
    • 4.2 Global CAR T-Cell Therapy Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States CAR T-Cell Therapy Market Size (2014-2019)
    • 5.2 CAR T-Cell Therapy Key Players in United States
    • 5.3 United States CAR T-Cell Therapy Market Size by Type
    • 5.4 United States CAR T-Cell Therapy Market Size by Application

    6 Europe

    • 6.1 Europe CAR T-Cell Therapy Market Size (2014-2019)
    • 6.2 CAR T-Cell Therapy Key Players in Europe
    • 6.3 Europe CAR T-Cell Therapy Market Size by Type
    • 6.4 Europe CAR T-Cell Therapy Market Size by Application

    7 China

    • 7.1 China CAR T-Cell Therapy Market Size (2014-2019)
    • 7.2 CAR T-Cell Therapy Key Players in China
    • 7.3 China CAR T-Cell Therapy Market Size by Type
    • 7.4 China CAR T-Cell Therapy Market Size by Application

    8 Japan

    • 8.1 Japan CAR T-Cell Therapy Market Size (2014-2019)
    • 8.2 CAR T-Cell Therapy Key Players in Japan
    • 8.3 Japan CAR T-Cell Therapy Market Size by Type
    • 8.4 Japan CAR T-Cell Therapy Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia CAR T-Cell Therapy Market Size (2014-2019)
    • 9.2 CAR T-Cell Therapy Key Players in Southeast Asia
    • 9.3 Southeast Asia CAR T-Cell Therapy Market Size by Type
    • 9.4 Southeast Asia CAR T-Cell Therapy Market Size by Application

    10 India

    • 10.1 India CAR T-Cell Therapy Market Size (2014-2019)
    • 10.2 CAR T-Cell Therapy Key Players in India
    • 10.3 India CAR T-Cell Therapy Market Size by Type
    • 10.4 India CAR T-Cell Therapy Market Size by Application

    11 Central & South America

    • 11.1 Central & South America CAR T-Cell Therapy Market Size (2014-2019)
    • 11.2 CAR T-Cell Therapy Key Players in Central & South America
    • 11.3 Central & South America CAR T-Cell Therapy Market Size by Type
    • 11.4 Central & South America CAR T-Cell Therapy Market Size by Application

    12 International Players Profiles

    • 12.1 Celgene (Juno Therapeutics)
      • 12.1.1 Celgene (Juno Therapeutics) Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 CAR T-Cell Therapy Introduction
      • 12.1.4 Celgene (Juno Therapeutics) Revenue in CAR T-Cell Therapy Business (2014-2019)
      • 12.1.5 Celgene (Juno Therapeutics) Recent Development
    • 12.2 Novartis
      • 12.2.1 Novartis Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 CAR T-Cell Therapy Introduction
      • 12.2.4 Novartis Revenue in CAR T-Cell Therapy Business (2014-2019)
      • 12.2.5 Novartis Recent Development
    • 12.3 Gilead (Kite Pharma)
      • 12.3.1 Gilead (Kite Pharma) Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 CAR T-Cell Therapy Introduction
      • 12.3.4 Gilead (Kite Pharma) Revenue in CAR T-Cell Therapy Business (2014-2019)
      • 12.3.5 Gilead (Kite Pharma) Recent Development
    • 12.4 Pfizer
      • 12.4.1 Pfizer Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 CAR T-Cell Therapy Introduction
      • 12.4.4 Pfizer Revenue in CAR T-Cell Therapy Business (2014-2019)
      • 12.4.5 Pfizer Recent Development
    • 12.5 CARsgen Therapeutics
      • 12.5.1 CARsgen Therapeutics Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 CAR T-Cell Therapy Introduction
      • 12.5.4 CARsgen Therapeutics Revenue in CAR T-Cell Therapy Business (2014-2019)
      • 12.5.5 CARsgen Therapeutics Recent Development
    • 12.6 Autolus Therapeutics
      • 12.6.1 Autolus Therapeutics Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 CAR T-Cell Therapy Introduction
      • 12.6.4 Autolus Therapeutics Revenue in CAR T-Cell Therapy Business (2014-2019)
      • 12.6.5 Autolus Therapeutics Recent Development
    • 12.7 Aurora BioPharma
      • 12.7.1 Aurora BioPharma Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 CAR T-Cell Therapy Introduction
      • 12.7.4 Aurora BioPharma Revenue in CAR T-Cell Therapy Business (2014-2019)
      • 12.7.5 Aurora BioPharma Recent Development
    • 12.8 Sorrento Therapeutics
      • 12.8.1 Sorrento Therapeutics Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 CAR T-Cell Therapy Introduction
      • 12.8.4 Sorrento Therapeutics Revenue in CAR T-Cell Therapy Business (2014-2019)
      • 12.8.5 Sorrento Therapeutics Recent Development
    • 12.9 Mustang Bio
      • 12.9.1 Mustang Bio Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 CAR T-Cell Therapy Introduction
      • 12.9.4 Mustang Bio Revenue in CAR T-Cell Therapy Business (2014-2019)
      • 12.9.5 Mustang Bio Recent Development
    • 12.10 Bluebird Bio
      • 12.10.1 Bluebird Bio Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 CAR T-Cell Therapy Introduction
      • 12.10.4 Bluebird Bio Revenue in CAR T-Cell Therapy Business (2014-2019)
      • 12.10.5 Bluebird Bio Recent Development
    • 12.11 Collectis
    • 12.12 Allogene Therapeutics
    • 12.13 Celyad

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Chimeric antigen receptor T cells (also known as CAR T cells) are T cells that have been genetically engineered to produce an artificial T-cell receptor. Chimeric antigen receptors (CARs, also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors) are receptor proteins that have been engineered to give T cells the new ability to target a specific protein. The receptors are chimeric because they combine both antigen-binding and T-cell activating functions into a single receptor. CAR-T cell therapy uses T cells engineered with CARs for cancer therapy. The premise of CAR-T immunotherapy is to modify T cells to recognize cancer cells in order to more effectively target and destroy them. Scientists harvest T cells from people, genetically alter them, then infuse the resulting CAR-T cells into patients to attack their tumors. CAR-T cells can be either derived from T cells in a patient's own blood (autologous) or derived from the T cells of another healthy donor (allogenic). Once isolated from a person, these T cells are genetically engineered to express a specific CAR, which programs them to target an antigen that is present on the surface of tumors. For safety, CAR-T cells are engineered to be specific to an antigen expressed on a tumor that is not expressed on healthy cells.
      In 2018, the global CAR T-Cell Therapy market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global CAR T-Cell Therapy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the CAR T-Cell Therapy development in United States, Europe and China.

      The key players covered in this study
      Celgene (Juno Therapeutics)
      Novartis
      Gilead (Kite Pharma)
      Pfizer
      CARsgen Therapeutics
      Autolus Therapeutics
      Aurora BioPharma
      Sorrento Therapeutics
      Mustang Bio
      Bluebird Bio
      Collectis
      Allogene Therapeutics
      Celyad

      Market segment by Type, the product can be split into
      Allogeneic
      Autologous

      Market segment by Application, split into
      Hospitals
      Cancer Research Centers
      Others

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global CAR T-Cell Therapy status, future forecast, growth opportunity, key market and key players.
      To present the CAR T-Cell Therapy development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of CAR T-Cell Therapy are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now